January 2019


An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds

Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol

Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?

 

February 2019


The Internal Validity of Discrete Choice Experiment Data- A Testing Tool for Quantitative Assessments

Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs

Perceptions of Response Burden Associated with Completion of Patient-Reported Outcome Assessments in Oncology

 

March 2019


Comparative Effectiveness of Computed Tomography Versus Ultrasound-Guided Percutaneous Radiofrequency Ablation Among Medicare Patients 65 Years of Age or Older With Hepatocellular Carcinoma

Determining the Comparative Value of Pharmaceutical Risk-Sharing Policies in Non–Small Cell Lung Cancer Using Real-World Data

Distribution of the EQ-5D-5L Profiles and Values in Three Patient Groups

 

April 2019


A Review of Clinical Trials With an Adaptive Design and Health Economic Analysis

Estimating Joint Health Condition Utility Values

Understanding Patients' Preferences: A Systematic Review of Psychological Instruments Used in Patients' Preference and Decision Studies

 

May 2019


Value in Health Anniversary Issue

 

June 2019


Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?

New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options?

Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy

Comparing the Noncomparable: The Need for Equivalence Measures That Make Sense in Health-Economic Evaluations

 

July 2019


Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?

Machine Learning for Health Services Researchers

 

August 2019


Per-Prescription Drug Expenditure by Source of Payment and Income Level in the United States, 1997 to 2015

An Ethical Analysis of Coverage With Evidence Development

Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment

Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration

 

September 2019


As Value Assessment Frameworks Evolve, Are They Finally Ready for Prime Time?

Barriers and Facilitators to Model Replication Within Health Economics

Are Healthcare Choices Predictable? The Impact of Discrete Choice Experiment Designs and Models

 

October 2019


A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management

On the Optimization of Bayesian D-Efficient Discrete Choice Experiment Designs for the Estimation of QALY Tariffs That Are Corrected for Nonlinear Time Preferences

Implementing Patient-Reported Outcome Measures in Clinical Breast Cancer Care: A Systematic Reviews

 

November 2019


Cannabis and Health Research: Rapid Progress Requires Innovative Research Designs

Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward

Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions

 

December 2019


Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?

Excess Costs and Economic Burden of Obesity-Related Cancers in the United States

How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×